|About Us | Location | Request Information | Site Map|
Past Clinical Studies
These are studies that have been completed and are no longer enrolling.
DNA/RNA/SERUM/PLASMA/URINE BANKING - Samples are collected anonymously from individuals who have Alzheimer's disease and stored for future research to understand diagnostic and vulnerability markers for the disease, enhance the understanding of treatment response and side effects, and develop new drugs.
COMPUTERIZED ADAS - This study to develop a computerized version of a standard paper-and-pencil test of memory and intellectual function. The advantages of computerization include better, faster, and error-free measurements.
HOMOCYSTEINE REDUCTION & SLOWING COGNITIVE DECLINE (ADCS Clinical Trial) - This 18 month trial looks at whether reducing homocysteine levels in blood might improve memory in individuals with mild to moderate Alzheimer's disease. Participants may be taking Reminyl, Exelon, Aricept, or Namenda (memantine).
XALIPRODEN - This 21 month long study assesses the efficacy on cognitive function of xaliproden compared to placebo in patients with mild-to-moderate dementia of the Alzheimer's disease. Participants can be taking Reminyl, Exelon, Aricept, or Namenda (memantine).
MILD COGNITIVE IMPAIRMENT STUDY (ADCS Clinical Trial) - this study will evaluate the efficacy and safety of vitamin E and donepezil, administered daily, to delay the clinical diagnosis of Alzheimer's disease when administered orally.
MILD COGNITIVE IMPAIRMENT NORMAL CONTROL STUDY (ADCS Clinical Trial) - the primary goal of this study is to determine the utility, sensitivity, and validity of newly developed or improved assessment instruments designed to evaluate clinical improvement in pharmacologic trials with Mild Cognitive Impairment subjects. The measures will be evaluated in MCI subjects through their inclusion as secondary outcomes in a multi-site clinical trial that will determine whether high doses of vitamin E or Aricept can prevent or delay progression to clinically evident Alzheimer's disease.
NON-STEROIDAL STUDY (ADCS Clinical Trial) - Evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer's disease along with a number of epidemiological studies suggests that non-steroidal anti-inflammatory drugs (NSAIDs) may slow the rate of cognitive deterioration.
CATIE - this is a study for individuals who have Alzheimer's disease and are experiencing behavioral problems, such as agitation, delusions, hallucinations or aggressive behavior. This is a 36 week study where the patient will receive FDA approved medication.
PREVENTION INSTRUMENTS(ADCS Clinical Trial) - the primary objective of this study is to conduct a "simulated" Alzheimer's Disease prevention clinical trial in 650 healthy, nondemented elderly subjects who are 75 years or older. The results of this simulated prevention trial will be used in the validation of the new, experimental outcome measures. The primary outcome of the simulated prevention trial is conversion to dementia, based on DSM IV criteria.
For more information please contact the
U.S.C. Geriatric Studies Center